Results 61 to 70 of about 22,886 (216)

Dual cross‐sectional and longitudinal perspective on the continuum of HIV care to disentangle natural epidemic evolution from real progress, Belgium 2014–2022

HIV Medicine, EarlyView.
Abstract Introduction This study provides a comprehensive overview of HIV care by combining cross‐sectional and longitudinal continuum of care (CoC) analyses. Methods Using national surveillance data 2014–2022, a five‐stage cross‐sectional CoC was calculated among people living with HIV (incl.
D. Van Beckhoven, B. Serrien, R. Demeester, J. Van Praet, P. Messiaen, G. Darcis, S. Henrard, P. De Munter, A. Libois, J. Deblonde   +9 more
wiley   +1 more source

CD8+ T lymphocyte responses target functionally important regions of Protease and Integrase in HIV-1 infected subjects

Journal of Translational Medicine, 2004
Background CD8+ T cell responses are known to be important to the control of HIV-1 infection. While responses to reverse transcriptase and most structural and accessory proteins have been extensively studied, CD8 T cell responses specifically directed to
Yu Xu G, Fitzpatrick Cecily A, Rathod Almas, Addo Marylyn M, Rodriguez William R, Perkins Beth, Rosenberg Eric S, Altfeld Marcus, Walker Bruce D   +8 more
doaj   +1 more source

How HIV-1 Integrase Associates with Human Mitochondrial Lysyl-tRNA Synthetase

Viruses, 2020
Replication of human immunodeficiency virus type 1 (HIV-1) requires the packaging of tRNALys,3 from the host cell into the new viral particles. The GagPol viral polyprotein precursor associates with mitochondrial lysyl-tRNA synthetase (mLysRS) in a ...
Xaysongkhame Phongsavanh, Noha Al-Qatabi, Mohammed Samer Shaban, Fawzi Khoder-Agha, Merwan El Asri, Martine Comisso, Raphaël Guérois, Marc Mirande   +7 more
doaj   +1 more source

Antiretroviral therapy use, self‐reported adherence, and viral suppression among women living with HIV in Canada

HIV Medicine, EarlyView.
Abstract Background Traditionally, ≥95% adherence was recommended for viral suppression (VS). Newer antiretroviral therapy (ART) is now being increasingly prescribed and may be more forgiving of lower adherence. The lifelong nature of ART presents adherence challenges, particularly for women living with HIV. We aimed to describe ART use and examine the
Maysaloun Mokaddam, Nadine Kronfli, Nancy L. Sheehan, Araceli Gonzalez Reyes, Danièle Dubuc, Mona Loutfy, Angela Kaida, Alexandra de Pokomandy, on behalf of the CHIWOS research team, Rahma Abdul‐Noor, Aranka Anema, Jonathan Angel, Dada Mamvula Bakombo, Fatimatou Barry, Greta Bauer, Kerrigan Beaver, Marc Boucher, Isabelle Boucoiran, Jason Brophy, Lori Brotto, Ann N. Burchell, Claudette Cardinal, Allison Carter, Lynne Cioppa, Tracey Conway, José Côté, Jasmine Cotnam, Cori d'Ambrumenil, Janice Dayle, Erin Ding, Danièle Dubuc, Janice Duddy, Mylène Fernet, Annette Fraleigh, Peggy Frank, Brenda Gagnier, Marilou Gagnon, Jacqueline Gahagan, Claudine Gasingirwa, Nada Gataric, Rebecca Gormley, Saara Greene, Danielle Groleau, Charlotte Guerlotté, Trevor Hart, Catherine Hankins, Emily Heer, Robert S. Hogg, Terry Howard, Shazia Islam, Joseph Jean‐Gilles, Hermione Jefferis, Evin Jones, Charu Kaushic, Mina Kazemi, Mary Kestler, Maxime Kiboyogo, Marina Klein, Nadine Kronfli, Gladys Kwaramba, Gary Lacasse, Ashley Lacombe‐Duncan, Melanie Lee, Rebecca Lee, Jenny Li, Viviane Lima, Elisa Lloyd‐Smith, Carmen Logie, Evelyn Maan, Valérie Martel‐Lafrenière, Carrie Martin, Renee Masching, Lyne Massie, Melissa Medjuck, Brigitte Ménard, Cari L. Miller, Judy Mitchell, Gerardo Mondragon, Deborah Money, Ken Monteith, Marvelous Muchenje, Florida Mukandamutsa, Mary Ndung'u, Valerie Nicholson, Kelly O'Brien, Nadia O'Brien, Gina Ogilvie, Susanna Ogunnaike‐Cooke, Joanne Otis, Rebeccah Parry, Sophie Patterson, Angela Paul, Doris Peltier, Neora Pick, Alie Pierre, Jeff Powis, Karène Proulx‐Boucher, Corinna Quan, Jesleen Rana, Eric Roth, Danielle Rouleau, Geneviève Rouleau, Sergio Rueda, Kate Salters, Margarite Sanchez, Roger Sandre, Jacquie Sas, Édénia Savoie, Paul Sereda, Stephanie Smith, Marcie Summers, Wangari Tharao, Christina Tom, Cécile Tremblay, Jason Trigg, Sylvie Trottier, Angela Underhill, Anne Wagner, Sharon Walmsley, Clara Wang, Kath Webster, Wendy Wobeser, Denise Wozniak, Mark H. Yudin, Wendy Zhang, Julia Zhu   +125 more
wiley   +1 more source

Metabolic syndrome and Pathobiological Determination of Atherosclerosis in Youth risk score in adolescents with and without perinatally acquired HIV in the Cape Town Adolescent and Antiretroviral Cohort (CTAAC)‐Heart study

HIV Medicine, EarlyView.
Abstract Background Limited data exist describing metabolic syndrome (MetS) and Pathobiological Determinants of Atherosclerosis in Youth (PDAY) coronary arteries (CA) and abdominal aorta (AA) risk scores in youth with HIV in sub‐Saharan Africa.
Sahera Dirajlal‐Fargo, Mothabisi Nyathi, Shan Sun, Lauren Balmert Bonner, Morné Kahts, Nana Akua Asafu‐Agyei, Nomawethu Jele, Emma Carkeek, Justine Legbedze, Grace A. McComsey, Matthew Feinstein, Landon Myer, Ntobeko A. B. Ntusi, Heather J. Zar, Jennifer Jao   +14 more
wiley   +1 more source

HIV integrase and the swan song of the CD4 T cells? [PDF]

Retrovirology, 2013
T cell apoptosis represents one pathophysiological mechanism associated with AIDS. Herein, we discuss the recent report published by A. Cooper et al. in Nature (June 2013) regarding HIV viral DNA integration-mediated apoptosis.
Estaquier, Jérôme, Zaunders, John, Laforge, Mireille   +2 more
openaire   +5 more sources

Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors

mBio, 2017
Resistance to the integrase strand transfer inhibitors raltegravir and elvitegravir is often due to well-identified mutations in the integrase gene. However, the situation is less clear for patients who fail dolutegravir treatment.
Isabelle Malet, Frédéric Subra, Charlotte Charpentier, Gilles Collin, Diane Descamps, Vincent Calvez, Anne-Geneviève Marcelin, Olivier Delelis   +7 more
doaj   +1 more source

Comparison of treatment‐emergent resistance‐associated mutations and discontinuation due to adverse events among integrase strand transfer inhibitor‐based single‐tablet regimens and cabotegravir + rilpivirine for the treatment of virologically suppressed people with HIV: A systematic literature review and network meta‐analysis

HIV Medicine, EarlyView.
Abstract Objective This study evaluated rates of treatment‐emergent resistance‐associated mutations (TE‐RAMs) and discontinuation due to adverse events (DC‐AEs) across integrase strand transfer inhibitor (INSTI)‐based single‐tablet regimens and injectable cabotegravir + rilpivirine (CAB + RPV) in virologically suppressed people with HIV.
Ishfaq Rashid, Nathan R. Unger, Connor Willis, Teerapon Dhippayom, Moti Ramgopal, Elizabeth M. Sherman, Nicholas Yared, Rachel Safran, Edwin Swiatlo, Amy R. Weinberg, Soodi Navadeh, Howard Weston Schmutz, Nathorn Chaiyakunapruk   +12 more
wiley   +1 more source

Willingness to participate in clinical trials and expectations towards antiretroviral therapy among heavily treatment‐experienced people living with HIV: A feasibility survey

HIV Medicine, EarlyView.
Abstract Introduction As life expectancy among persons with HIV on antiretroviral therapy (ART) is increasing, comorbidities and polypharmacy increase. Drug–drug interactions (DDIs) are common among persons with HIV with a history of virological failure, since many are receiving boosted ART.
Marie Ballif, Manuela Correia da Silva Saúde, David Haerry, Marcel Stoeckle, Patrick Schmid, Dominique Braun, Alexandra Calmy, Gilles Wandeler, Bernard Surial   +8 more
wiley   +1 more source

HIV resistance to raltegravir

European Journal of Medical Research, 2009
Similar to all antiretroviral drugs, failure of raltegravirbased treatment regimens to fully supress HIV replication almost invariably results in emergence of HIV resistance to this new drug.
Clavel François
doaj   +1 more source